SEOUL PHARMA CO.,LTD Logo

SEOUL PHARMA CO.,LTD

Develops pharmaceuticals with innovative Orally Disintegrating Film (ODF) tech for global markets.

018680 | KO

Overview

Corporate Details

ISIN(s):
KR7018680009
LEI:
Country:
South Korea
Address:
충청북도 청주시 흥덕구 오송읍 오송생명6로 124-31 서울제약 오송공장, 청주시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Seoul Pharma Co., Ltd. is a pharmaceutical company that manufactures and distributes a range of pharmaceutical products for both domestic and international markets. The company specializes in advanced Drug Delivery System (DDS) technologies, with a particular focus on its Orally Disintegrating Film (ODF) platform. Its product portfolio includes over-the-counter medications and prescription drugs across various therapeutic areas, including vitamins, antibiotics, and treatments for the cardiovascular and circulatory systems. Seoul Pharma operates in compliance with global Good Manufacturing Practice (GMP) standards, aiming to improve global health through its innovative technologies.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 953.1 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 915.1 KB
2025-04-18 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집공고
Korean 92.8 KB
2025-03-28 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 22.4 KB
2025-03-20 00:00
Audit Report / Information
감사보고서제출
Korean 18.5 KB
2025-03-20 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 480.3 KB
2025-03-17 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 14.3 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 11.2 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 89.8 KB
2025-03-13 00:00
Pre-Annual General Meeting Information
주주총회집중일개최사유신고
Korean 5.5 KB
2025-02-07 00:00
Regulatory News Service
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 11.1 KB
2024-12-13 00:00
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
Korean 4.5 KB
2024-11-14 00:00
Quarterly Report
분기보고서 (2024.09)
Korean 818.8 KB
2024-08-14 00:00
Interim Report
반기보고서 (2024.06)
Korean 836.4 KB
2024-05-14 00:00
Quarterly Report
분기보고서 (2024.03)
Korean 734.1 KB

Automate Your Workflow. Get a real-time feed of all SEOUL PHARMA CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SEOUL PHARMA CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SEOUL PHARMA CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

IMMUCELL CORP /DE/ Logo
Develops biotech health products for disease prevention in dairy and beef cattle.
United States of America
ICCC
Immuneering Corp Logo
Clinical-stage oncology firm using bioinformatics to develop oral MEK inhibitors for solid tumors.
United States of America
IMRX
ImmuneOncia Therapeutics, Inc. Logo
A biopharma firm developing immune checkpoint inhibitors for cancer immunotherapy.
South Korea
424870
ImmunityBio, Inc. Logo
Develops immunotherapies activating the immune system to fight cancer and infectious diseases.
United States of America
IBRX
Immuno-Biological Laboratories Co., Ltd. Logo
Develops and supplies immunological reagents and diagnostics for research and drug discovery.
Japan
4570
Immunocore Holdings plc Logo
Pioneering TCR bispecific immunotherapies for cancer, infectious, and autoimmune diseases.
United States of America
IMCR
Immunome Inc. Logo
Develops targeted oncology therapies, like ADCs, for cancers with high unmet needs.
United States of America
IMNM
Immunovant, Inc. Logo
Developing novel, FcRn-targeted therapies for people with autoimmune diseases.
United States of America
IMVT
Immuron Ltd Logo
Develops oral antibodies from bovine colostrum for digestive and immune health.
United States of America
IMRN
IMPACT BIOMEDICAL INC. Logo
Develops biopharma, preservatives, and bioplastics for healthcare and pathogen protection.
United States of America
IBO

Talk to a Data Expert

Have a question? We'll get back to you promptly.